Layfferon solution and / v / m / subconjunctival injection / instillation in the eye piece 5 amp 3mln.me

$32.23

Layfferon solution and / v / m / subconjunctival injection / instillation in the eye piece 5 amp 3mln.me

Quantity:

SKU: 0827904580 Categories: , , Tags: ,

Description

Composition
Active substance:
1 vial of lyophilisate contains: 0.5 million IU, MU 1, 3 million IU, or 5 million IU of interferon alfa-2b recombinant human. 1 ampoule of solution contains: 500 000 IU 1,000,000 IU 3,000,000 IU or 5,000,000 IU of interferon alpha-2 human recombinant.
Excipients:
1 vial of lyophilisate contains: sodium chloride – 9.2 mg; sodium hydrogen phosphate dodecahydrate (sodium phosphate dibasic 12-water) – 2.74 mg; sodium dihydrogen phosphate dihydrate (monobasic sodium phosphate 2 aq) – 0.37 mg; Dextran with a molecular weight of from 30,000 to 40,000 (in the form of a solution “Reopoligljukin” containing 100 mg / ml of dextran in 0.9% sodium chloride solution) – 8.0 mg; Sorbitol (D-sorbitol) – 3.0 mg, carbamide (urea) – 0.1 mg. 1 ampoule solution comprising: Sodium Chloride – 7.5mg; sodium hydrogenphosphate dodecahydrate – 4.53 mg; sodium dihydrogen phosphate dihydrate – 1.5 mg; Disodium edetate – 0.1 mg; Tween 80 – 0.1 mg; oksiglutation – 0.03 mg; Nipagin – 1.0 mg; Water for injection – up to 1 ml.
Description:
The preparation is colorless, transparent or weakly opalescent solution.
Product form:
Lyophilizate for preparation of solution for intramuscular administration, subconjunctival administration and instillation into the eye.
The ampoules of 0.5 million IU; 1 million IU; 3 million IU; 5 million IU; 5 vials per blister film of polyvinylchloride (PVC); 1 or 2 stripes package together with instructions for use and ampulnam knife or lancet, in a cardboard bundle. If the vials are ring fracture or fracture point, scarifier in the package do not invest.
In glass vials at 0.5 million IU; 1 million IU; 3 million IU; 5 million IU. The vials were capped with rubber stoppers and aluminum caps rolled up; 5 vials in a blister made of PVC; 1 blister together with instructions for use in a cardboard package.
Solution for intramuscular administration, subconjunctival administration and instillation into the eye.
The glass ampoule of 1 ml with an activity of 500,000 IU or 1,000,000 IU or 3,000,000 IU or 5,000,000 IU; 5 vials per blister film of polyvinylchloride (PVC); 1 or 2 stripes package together with instructions for use and lancet in a cardboard package. If the vials are ring fracture or fracture point, scarifier in the package do not invest.
Or 1 ampoule together with instructions for use and lancet in a cardboard package. If the vials are ring fracture or fracture point, scarifier in the package do not invest.
Or 1 ampoule together with instructions for use, lancet, single-use injection syringe and two sterile alcohol wipes for injection in a cardboard package. If the vials are ring fracture or fracture point, scarifier in the package do not invest.
In glass vials of 1 ml with an activity of 500,000 IU or 1,000,000 IU or 3,000,000 IU or 5,000,000 IU. The vials were capped with rubber stoppers and crimped aluminum caps; 5 vials in a blister made of PVC; 1 blister together with instructions for use in a cardboard package.
Or 1 bottle together with instructions for use in a cardboard package.
Or 1 bottle together with instructions for use, single-use injection syringe and two sterile alcohol wipes for injection in a cardboard package.
Contraindications
The drug is contraindicated: – in hypersensitivity to the drug; – severe forms of allergic diseases; – during pregnancy and lactation. Application of pregnancy and during breastfeeding
The drug is contraindicated during pregnancy and lactation.
Indications
Layfferon® used in combination therapy in adults: – in acute viral hepatitis B – moderate and severe forms of jaundice in the early period before the 5th day of jaundice (at a later date the appointment of the drug is less effective, the drug is not effective in developing hepatic coma and cholestatic during disease); – protracted in acute hepatitis B and C, chronic active hepatitis B and C, including the delta agent without cirrhosis and signs of liver cirrhosis; – viral (influenza, adenovirus, enterovirus, herpes, mumps), viral and bacterial and mycoplasmal meningoencephalitis. Use of the drug is most effective during the first 4 days of the disease; – cancer kidney IV stage, hairy cell leukemia, malignant skin lymphoma (mycosis fungoides, Primary reticulosis, retikulosarkomatoze), Kaposi’s sarcoma, basal cell and squamous skin cancers, keratoacanthoma, chronic myeloid leukemia, histiocytosis Langerhans cells subleukemic mieloze, essential thrombocythemia; – multiple sclerosis; – for viral conjunctivitis, keratokonyunktivitah, keratitis, keratoiridocyklites, keratouveitis.
Layfferon® used in the treatment of children from 1 year: – acute lymphoblastic leukemia in remission after induction chemotherapy (4-5 month remission); – in juvenile respiratory papillomatosis of the larynx, beginning the next day after the removal of warts.
Interaction with other drugs
Interferon alpha-2b is able to reduce the activity of cytochrome P450 and, therefore, interfere with the metabolism of cimetidine, phenytoin dipyridamole, theophylline, diazepam, propranolol, warfarin, some cytostatics. May potentiate neurotoxic, myelotoxic or cardiotoxic action of drugs prescribed previously or simultaneously therewith. concomitant administration should be avoided with drugs depressing the central nervous system, immunosuppressive agents (including corticosteroids).
Drinking alcohol during treatment is not recommended.
Overdose
Cases of overdose were observed. Given that the active substance is interferon alpha-2b, the overdose may increase the severity of side effects.
Treatment: removal of preparation; if necessary symptomatic treatment.
pharmachologic effect
Pharmacological group:
MIP – cytokine.
Pharmacological properties:
Layfferon® has antiviral, anticancer, immunomodulatory activity.
Layfferon® when administered parenterally undergoes decomposition partially excreted unchanged, primarily via the kidneys. As with all interferons in individuals with prolonged use of the drug can cause the appearance of anti-interferon antibodies, which leads to a decrease in therapeutic effect.
Conditions of supply of pharmacies
Prescription.
side effects
For parenteral administration the drug may chills, fever, fatigue, headache, malaise, flu-like syndrome. These side effects partly cropped paracetamol or indomethacin.
The local application of the drug in the mucosa of the eye can conjunctival infection, hyperemia eye mucosa, isolated follicles, conjunctival edema of the lower arch.
In applying the drug may abnormal laboratory values, manifested by leukopenia, lymphopenia, thrombocytopenia, increased levels of alanine aminotransferase, alkaline phosphatase. For early detection of these abnormalities during therapy common clinical blood tests should be repeated every 2 weeks, and biochemical – every 4 weeks. As a rule, these changes are usually small, asymptomatic and reversible.
special instructions
Effects on ability to drive and use machines.
The period of application of the drug to patients experiencing fatigue, drowsiness or disorientation, should refrain from activities potentially hazardous activities that require high concentration and psychomotor speed reactions.
Storage conditions
Store in a dark place at a temperature of not higher than 8 ° C.
Keep out of the reach of children.
Dosing and Administration
Layfferon® administered intramuscularly in the center or at the lesion, subkonyunktivalno or topically.
lyophilisate:
Immediately prior to use the contents of the vials (bottles) with the lyophilisate is dissolved in water for injection or 0.9% sodium chloride solution (1 ml – when administered intramuscularly in the hearth, in 5 ml of – at subconjunctival and local administration). A solution of the drug should be colorless, with a faint opalescence without extraneous impurities and sediment. Dissolution time should be about 10 minutes.
Solution:
For topical application to the contents of the ampoule preparation with an activity of 1 million IU added 4 ml of sodium chloride 0.9% for injection. In the case of storage solution must preparation following the rules of asepsis and antisepsis, transfer contents of the vial into a sterile vial with a septum and the solution was stored in a refrigerator at 4-10 ° C for up to 12 hours.
intramuscular
In acute viral hepatitis B drug is administered at 1 million IU 2 times a day for 5-6 days and then the dose was reduced to 1 MU daily and injected for a further 5 days. If required, (after control blood biochemical studies) treatment may be continued at 1 million IU 2 times a week for 2 weeks. Heading dose is 15-21 MU.
When prolonged acute and chronic viral hepatitis B with exclusion of delta-agent and without cirrhosis drug is administered at 1 million IU 2 times per week for 1-2 months. If no effect treatment extend up to 3-6 months or after the 1-2 month treatment course similar to conduct 2-3 with 1-6 months interval.
In chronic viral hepatitis B delta agent without cirrhosis drug is administered at 0.5-1 million IU per day, 2 times a week for 1 month. Repeated treatment after 1-6 months.
In chronic viral hepatitis B with delta-agent and signs of liver cirrhosis drug is administered at 0.25-0.5 million IU per day, 2 times a week for 1 month. When you see signs of decompensation carry out similar refresher courses at intervals of not less than 2 months.
In acute protracted and chronically active hepatitis C without cirrhosis drug is administered at 3 MIU 3 times a week for 6-8 months. If no effect treatment extend to 12 months. Repeated treatment after 3-6 months.
When the viral, bacterial and viral and mycoplasmal meningoencephalitis drug is administered at 1 million IU 2 times a day for 10 days, in combination with antiviral and antibacterial chemotherapies. The dosage and treatment regimen established individually, depending on the severity of the patient’s condition.
When kidney cancer drug is used by 3 million IU daily for 10 days. Repeated courses of treatment (3-9 and more) is carried out at intervals of 3 weeks. Total amount of the preparation is from 120 to 300 MIU million IU or more.
When hairy cell leukemia drug is administered daily for 3-6 million. IU for 2 months. After normalization hemogram daily dose is reduced to 1-2 million IU. Then designate supportive therapy for 3 million IU 2 times a week for 6-7 weeks. The total amount of drug is 420-600 million IU or more.
In acute lymphoblastic leukemia in remission after induction chemotherapy (4-5 month remission) – 1 million IU 1 time per week for 6 months, then 1 every 2 weeks for 24 months. At the same time carry out maintenance chemotherapy.
In malignant lymphoma and Kaposi’s sarcoma is administered a preparation of 3 million IU per day every day for 10 days in combination with cytostatics (prospidin, cyclophosphamide) and glucocorticosteroids. When tumor stage mycosis fungoides, Reticulose primary and alternate expedient retikulosarkomatoze intramuscular administration of the preparation of 3 million IU intralesional and – at 2 million IU for 10 days.
In patients with mycosis fungoides eritrodermicheskoy step at higher temperatures than 39 ° C and in the case of acute process, the introduction of the drug should be stopped. In case of insufficient therapeutic effect after 10-14 days appoint a second course of treatment. After achieving the clinical effect of maintenance therapy is prescribed by 3 million IU weekly for 6-7 weeks.
In chronic myelogenous leukemia drug is administered at 3 million IU daily or 6 million IU every second day. Duration of treatment from 10 weeks to 6 months.
When Langerhans cell histiocytosis of drug administered by 3 MIU daily for 1 month. Repeated courses with 1-2-month intervals for 1-3 years.
When subleukemic mieloze and essential thrombocythemia correction hyperthrombocytosis – at 1 million IU daily or every other day for 1 to 20 days.
In juvenile laryngeal papillomatosis respiratory preparation is administered by 0.1-0.15 million IU per kg of body weight daily for 45-50 days, then at the same dosage three times a week for 1 month. The second and third courses are held at intervals of 2-6 months.
In multiple sclerosis, the drug is prescribed for 1 million IU pyramidal syndrome with 3 times a day, with cerebellar syndrome – 1-2 times a day for 10 days followed by administration of 1 million IU 1 time per week for 5-6 months. Total amount of the preparation is 50-60 MU.
Individuals with high pyrogenic reaction (39 ° C and above) for administering the drug to the simultaneous use of paracetamol or indomethacin.
perifocal introduction
When basal cell and squamous cell carcinoma, keratoacanthoma drug is injected under the lesion of 1 million IU 1 time per day every day for 10 days. In the case of pronounced local inflammatory reactions, injection under the lesion is carried out in 1-2 days. After completing this course, if necessary, carry out cryotherapy.
subconjunctival administration of
When stromal keratitis, keratoiridocyklites, keratouveitis administered subconjunctival injection preparation in a dose of 60 thousand. IU in a volume of 0.5 mL daily or every other day depending on the severity of the process. Injection is performed under local anesthesia 0.5% tetracaine solution. The course of treatment – from 15 to 25 injections.
topical application
For topical application, the contents of the ampoule (vial) with drug activity 1 million IU was dissolved in 5 ml of sodium chloride 0.9% for injection. In the case of storing the drug solution necessary Aseptically and antiseptics, transfer contents of the vial into a sterile vial with a septum and the solution was stored in a refrigerator at (4-10) ° C is not more than 12 hours.
Conjunctivitis and superficial keratitis affected eye conjunctiva applied 2 drops of solution 6-8 times a day. As the disappearance of inflammatory phenomena number of instillations reduced to 3-4 times a day. The course of treatment – 2 weeks.
PRECAUTIONS FOR ADMINISTRATION
In case of severe adverse reactions or preserving them for a long time, at the physician’s discretion, be temporary dose reduction (with a decrease in platelet count to less than 50,000 cells in 1 mm, the absolute neutrophil count below 750 cells in 1 l) or interrupt treatment (at reducing the number of platelets to less than 25,000 cells in 1 mm, the absolute neutrophil count below 500 cells in 1 l).
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

Layfferon

There are no reviews yet.

Add your review